It is established that sodium–glucose cotransporter-2 inhibitors (SGLT2-i) provide effective glycemic control and have been shown to reduce atherosclerotic events, hospitalizations for heart failure, cardiovascular mortality, and the progression of chronic kidney disease. This evidence concerns the gene SLC5A2 and heart failure.